Non-Small Cell Lung Cancer

Combination therapy demonstrates 35% reduction in lung cancer tumors

Published in Respiratory Therapeutics Week, December 12th, 2005

Point Therapeutics, Inc. (POTP) presented preclinical data on its lead product candidate talabostat, demonstrating antitumor activity when combined with either pemetrexed or erlotinib in a non-small cell lung cancer (NSCLC) xenograft model in immunodeficient mice. As a single agent, talabostat caused a 35% greater reduction in tumor size than pemetrexed alone.

Results were presented at a poster session at the AACR-EORTC-NCI International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, Pennsylvania.

As a single agent, talabostat caused a 35% greater reduction in tumor size than pemetrexed alone. Administration of 500 mg/kg of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Respiratory Therapeutics Week

Source: Respiratory Therapeutics Week (2005-12-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry